Sickle Cell Disease Effects on PT and aPTT
Sickle cell disease typically causes prolongation of both PT and aPTT, though the degree of prolongation varies with disease severity, clinical state, and individual patient factors. 1, 2, 3
Key Laboratory Findings
Prothrombin Time (PT)
- PT is frequently prolonged in SCD patients, with studies showing 38-100% of patients having abnormal values depending on clinical state 4
- The prolongation is more pronounced during vaso-occlusive crises compared to steady state 1, 2
- Mean PT values remain within or near normal laboratory ranges during steady state (approximately 13.2 ± 1.0 seconds) but can be significantly elevated during acute complications 1
- Severe anemia correlates with greater PT prolongation - patients with HbSS and severe anemia show significantly longer PT (p = 0.039) 2
Activated Partial Thromboplastin Time (aPTT)
- aPTT is consistently prolonged in SCD, with values around 47-52 seconds in steady state compared to 37-38 seconds in controls 5
- The prolongation is significantly more pronounced during vaso-occlusive crisis (52.24 ± 5.34 sec) versus steady state (47.76 ± 4.80 sec) 5
- Like PT, severe anemia correlates with greater aPTT prolongation (p = 0.041 in HbSS patients) 2
Phenotype-Specific Differences
The degree of coagulation abnormality varies by genotype:
- HbSS patients show the most significant abnormalities with higher PT and lower aPTT compared to HbSC phenotype (p = 0.01 and p = 0.03 respectively) 1
- HbSC and HbSβ-thalassemia patients typically have less pronounced changes 1
Underlying Mechanisms
The prolongations reflect multiple pathophysiologic processes:
Factor deficiencies are the primary driver:
- Factor V and Factor VII levels are significantly reduced in patients with prolonged PT 4
- Factor VII levels <50% were found in 4/8 patients with prolonged PT versus only 3/92 with normal PT (p = 0.001) 4
- These deficiencies likely result from hepatocellular dysfunction and increased consumption 4
Hypercoagulable state paradox: Despite prolonged screening tests, SCD patients are actually in a prothrombotic state evidenced by:
- Elevated D-dimer levels (standardized mean difference 0.87, p < 0.01) 3
- Reduced protein C (SMD -1.32, p < 0.01) and protein S (SMD -1.45, p < 0.01) 3
- Resistance to activated protein C 6
Clinical Implications
Important Caveats
PT and aPTT do not reflect true bleeding risk - these tests measure only part of the hemostatic system and don't capture the rebalanced hemostasis in SCD 7
Clinical state matters significantly:
Pregnancy effects: Pregnant women with SCD show lower mean PT (12.3 ± 0.6 s vs. 13.2 ± 1.0 s, p = 0.01) compared to non-pregnant women 1
Perioperative Considerations
Six of seven children with prolonged PT who underwent surgery experienced significant intraoperative blood loss (p = 0.04), suggesting these abnormalities may have clinical relevance in the surgical setting 4. However, this doesn't necessarily indicate routine correction is beneficial, as the bleeding may relate to surgical factors rather than coagulation defects.
Anticoagulation Monitoring
When SCD patients require anticoagulation (VTE incidence 11-17% in adults) 8:
- Standard PT/INR monitoring for warfarin remains appropriate 9
- aPTT for heparin monitoring follows usual protocols 10, 11
- Renal function must be considered - alternative anticoagulants should be used if CrCl >95 mL/min with edoxaban 8
Bottom Line
The prolonged PT and aPTT in SCD reflect underlying factor deficiencies and hepatic dysfunction, not a simple bleeding tendency. These abnormalities are most pronounced during acute illness and severe anemia. Do not reflexively correct these values with plasma products - SCD patients maintain rebalanced hemostasis despite abnormal screening tests, and correction may paradoxically increase thrombotic risk given their underlying hypercoagulable state.